Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres
M. Masoli, B. Castell, D. Halpin, C. Chamberlain, R. Stone, R. Shrimanker, L. Dobson, K. Cutland, J. Suntharalingam, R. Carver, I. Kasujee (Plymouth, Exeter, Taunton, Torbay, Bath, Frimley/Camberley, United Kingdom)
Source: Annual Congress 2012 - Asthma: risk factors and effect of anti-IgE
Session: Asthma: risk factors and effect of anti-IgE
Session type: Poster Discussion
Number: 226
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Masoli, B. Castell, D. Halpin, C. Chamberlain, R. Stone, R. Shrimanker, L. Dobson, K. Cutland, J. Suntharalingam, R. Carver, I. Kasujee (Plymouth, Exeter, Taunton, Torbay, Bath, Frimley/Camberley, United Kingdom). Omalizumab improves lung function in severe persistent allergic (IgE-mediated) asthma patients: Pooled data from 5 UK centres. Eur Respir J 2012; 40: Suppl. 56, 226
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: